


Organized by:



Under the auspices:



# Melanoma Bridge



Naples, Royal Continental Hotel  
December 2<sup>nd</sup> - 4<sup>th</sup>, 2012



# BACKGROUND

## Melanoma Bridge Naples, December 2<sup>nd</sup> - 4<sup>th</sup> 2012

In the last years, when advancement in understanding the molecular basis of melanoma has made possible the identification of molecular targets and of active specific immunization with important implications in clinical practice, landmark progress has been made in the treatment of cancer and, melanoma in particular. Since then, new therapeutic approaches have been emerging from basic science and translating into clinical practice by active clinical investigation. To disclose and stimulate the discussion of new approaches and strategies in the field of melanoma, more than 40 international faculty members will join “Melanoma Bridge meeting”. After the first meeting “Melanoma Research: a bridge Naples-USA” (Naples, Dec 6-7th 2010) and the second edition “Melanoma Research: a bridge from Naples to the World” (Naples, Dec 5-6th 2011), “Melanoma Bridge 2012” will take place from December 2nd to 4th 2012 in Naples, jointly organized by Istituto Nazionale Tumori Fondazione “G. Pascale” and Fondazione Melanoma Onlus, together with the Society for ImmunoTherapy of Cancer (SITC) and the National Institute of Health (NIH) Presidents of the event are Paolo A. Ascierto (INT, Naples, Italy), Francesco M. Marincola (NIH, Bethesda, USA), and Nicola Mozzillo (INT, Naples, Italy) and, together with the Scientific Board, including well-known experts covering different areas and based in different Countries, aim at achieving a broad-based participation by various groups and societies sharing a clinical or basic interest in the immunology and the biology of the cancer microenvironment.

Attendees are expected from Italy and from all around the world. In addition, for the first time, representatives of melanoma patient associations are invited to join the event.



DECEMBER 2<sup>nd</sup>

# CME EVENT SCIENTIFIC PROGRAM



## DECEMBER 2<sup>nd</sup>

- 17:00 Opening Ceremony  
Chair: **Nicola Mozzillo**, **Franco Marincola**
- 17.10 La storia del melanoma in Italia raccontata da Pino Cascinelli  
**Natale Cascinelli**
- 17.30 State of the Art in target therapy for melanoma  
**Paolo A. Ascierto**
- 17.50 L'esperienza dei pazienti  
**Francesco Brancaccio**, *Responsabile Area Pazienti Fondazione Melanoma Onlus*
- 18.00 Melanoma & Research  
**Valerie Guild**, *President of the AIM at Melanoma Foundation*
- 18.10 Tavola Rotonda: Esperti e pazienti  
**Stefano Caldoro\***, *Presidente Regione Campania*  
**Francesco De Lorenzo\***, *Presidente FAVO*  
**Luigi De Magistris\***, *Sindaco di Napoli*  
**Michele Maio\***, *Presidente Eletto NIBIT, Network Italiano per la Bioterapia dei Tumori*

# CME EVENT SCIENTIFIC PROGRAM

**Giuseppe Palmieri**, Segretario IMI, Intergruppo Melanoma Italiano, Presidente Humana Onlus

**Carmine Pinto**, Segretario Nazionale AIOM, Associazione Italiana di Oncologia Medica

**Alessandro Testori \***, EORTC Melanoma Group

19.30 Award Ceremony  
*The Melanoma Foundation Honorary Lecture on Melanoma Research and Treatment*

20.00 *Welcome Cocktail*

20.30 *Congress Official Dinner*

*\* invited to participate*



DECEMBER 3<sup>rd</sup>

# CME EVENT SCIENTIFIC PROGRAM



## DECEMBER 3<sup>rd</sup>

- 9.00 Saluto delle Autorità  
*Tonino Pedicini, Direttore Generale INT Pascale Napoli*  
*Gennaro Ciliberto, Direttore Scientifico INT Pascale Napoli*  
*Gaetano Lombardi, Presidente CIV INT Pascale Napoli*  
*Nicola Mozzillo, Presidente Melanoma Bridge 2012*  
*Francesco Marincola, Presidente Melanoma Bridge 2012*  
*Paolo A. Ascierto, Presidente Melanoma Bridge 2012*

## MOLECULAR ADVANCES AND BIOMARKERS

Chairmen: *Magdalena Thurin, Franco Marincola*

- 9:30 Mage-A3 Antigen Specific Immunotherapy: spontaneous and induced immune response  
*Vincent Brichard*
- 10:00 Cancer/antigen expression and correlations with immune responses and clinical events  
*Sacha Gnjatic*
- 10:30 The melanoma tumor microenvironment: biomarkers to biology  
*Thomas F. Gajewski*
- 11:00 Biomarkers predicting response to immunotherapy  
*Helen Gogas*

# CME EVENT SCIENTIFIC PROGRAM

11:30 *Break*

11:45 Single Cell Network Profiling (SCNP): technology and its application to the development of cancer immunotherapy  
***Alessandra Cesano***

12:15 New Markers of Melanoma Metastasis  
***Mohamed Kashani Sabet***

12:45 How melanoma escapes from MAPK inhibition  
***Roger Lo***

13:15 *Lunch*

## **COMBINATION THERAPIES**

Chairmen: ***Paolo A. Ascierto, Nicola Mozzillo***

14:50 Current and Future Options for Adjuvant Therapy of Melanoma  
***John Kirkwood***

15:20 Combinatorial Immunotherapeutic strategies  
***Soldano Ferrone***



# CME EVENT SCIENTIFIC PROGRAM



- 15:50 BRAFV600E targeted therapy and adoptive cell transfer immunotherapy  
**Nicolas Acquavella**
- 16:20 Oncolytic Viral Therapy for the Treatment of Melanoma  
**Howard Kaufman**
- 16:50 *Break*
- 17:00 Drug development in the era of molecular medicine: lessons from BRAF inhibitors in melanoma  
**Igor Puzanov**
- 17:30 Effects of paradoxical activation of the MAPK pathway with BRAF inhibitors  
**Antoni Ribas**
- 18:00 Strategies to overcome BRAF inhibitor resistance with combination therapy  
**Jeff Sosman**
- 18:30 Novel Molecular Targets in Melanoma  
**Grant McArthur**
- 19:00 Closing remarks

# CME EVENT SCIENTIFIC PROGRAM

## DECEMBER 4<sup>th</sup>

### NOVEL CONCEPT

Chairmen: *Nicola Normanno, Giuseppe Palmieri*

- 9:20 Fondazione Melanoma award lecture: Inflammation and the commensal flora affect the tumor microenvironment and the response to therapy  
*Giorgio Trinchieri*
- 9:50 Immuno-stromal modulation: the balance can tip either way  
*Lex Eggermont*
- 10:20 Intratumour Heterogeneity: is it relevant?  
*James Larkin*
- 10:50 Brain metastases in the era of molecularly targeted and immunomodulatory therapies  
*Kim Margolin*
- 11:20 Phase III, Randomized, Open-Label, Multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM)  
*Michele Del Vecchio*



# CME EVENT SCIENTIFIC PROGRAM



11:30 *Break*

11:45 The complexity of tumor biology challenge immune responsiveness  
***Ena Wang***

12:00 Diversity and avidity: frequently neglected, yet key parameters of the anti-tumor T cell response  
***Paul V. Lehmann***

12:15 Evaluation of therapeutic strategies in a genetically engineered mouse model for melanoma  
***Rienk Offringa***

12:45 Technological development, research and melanoma treatment: introperative 3D-Spect, dendritic cells and elektrochemotherapy  
***Lorenzo Borgognoni***

13:10 Chemosaturation Therapy: Creating New Options in the Management of Patients with Liver Dominant Disease  
***Mark Faries***

13:30 *Lunch*

# CME EVENT SCIENTIFIC PROGRAM

## BRIDGE BETWEEN MELANOMA AND COLO-RECTAL CANCER: BIOLOGY OF TUMOR MICROENVIRONMENT

Chairmen: **Fernando Vidal-Vanaclocha, Gennaro Ciliberto**

- 14:30 Selective biomarkers and immune modulatory molecules as targets for (immune) therapies of melanoma  
**Barbara Seliger**
- 15:00 Effects of pH regulation on melanoma immunity  
**Licia Rivoltini**
- 15:30 Cancer related Inflammation in tumor progression  
**Alberto Mantovani**
- 16:00 Vaccine strategy targeting antigens expressed by tumors in their microenvironment  
**Bernard A. Fox**
- 16:30 *Break*
- 16:45 Optimization of synthetic therapeutic vaccines for viral and non-viral cancer  
**Cornelis Melief**



DECEMBER 4<sup>th</sup>

# CME EVENT SCIENTIFIC PROGRAM



17:15 The MESOT-TREM Study: anti-CTLA-4 treatment of chemotherapy-resistant mesothelioma patients.

***Luana Calabrò***

17:45 The hepatic metastasis microenvironment for melanoma and colon cancer cells

***Fernando Vidal-Vanaclocha***

18:15 A new approach for the classification of cancer in the era of immunotherapy

***Jérôme Galon***

18:45 Closing remarks

19:15 CME Test



# PRESIDENTS and SCIENTIFIC BOARD

## **PRESIDENTS:**

**Paolo A. Ascierto** 🇮🇹

*Vice Director of the Unit of Medical Oncology and Innovative Therapies, Istituto Tumori Fondazione Pascale, Naples, Italy*

**Francesco M. Marincola** 🇺🇸

*Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the National Institutes of Health in Bethesda, Maryland*

**Nicola Mozzillo** 🇮🇹

*Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy*

## **SCIENTIFIC BOARD:**

**Paolo A. Ascierto** 🇮🇹

*Vice Director of the Unit of Medical Oncology and Innovative Therapies, Istituto Tumori Fondazione Pascale, Naples, Italy*

**Gennaro Ciliberto** 🇮🇹

*Scientific Director of the National Cancer Institute “Fondazione G. Pascale” of Naples, Italy*

**Bernard A. Fox** 🇺🇸

*Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon*



# PRESIDENTS and SCIENTIFIC BOARD



**Jérôme Galon** 

*Research Director at INSERM (National Institute of Health and Medical Research), Paris, France*

**John M. Kirkwood** 

*Professor of Clinical and Translational Science, Clinical and Translational Science Institute, University of Pittsburgh, Pennsylvania*



**Francesco M. Marincola** 

*Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the National Institutes of Health in Bethesda, Maryland*

**Nicola Mozzillo** 

*Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy*



**Antoni Ribas** 

*Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles, California*

**Giorgio Trinchieri** 

*Director of the Cancer and Inflammation Program and Chief of the Laboratory of Experimental Immunology, NCI, NIH, Maryland*

# PRESIDENTS and SCIENTIFIC BOARD

**Fernando Vidal-Vanaclocha** 🇪🇸

*Professor of Cell Biology and Human Histology, Vice Dean for Research and International Affairs and Scientific Director of the Institute of Applied Molecular Medicine (IMMA) at the CEU-San Pablo University School of Medicine, Madrid, Spain*

**Ena Wang** 🇺🇸

*Director of Molecular Science, Infectious Diseases and Immunogenetics Section, Department of Transfusion Medicine, CC, NIH, Maryland*



# SPEAKERS and MODERATORS



**Nicolas Acquavella** 

*Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

**Lorenzo Borgognoni** 

*Plastic Surgery Unit, Regional Melanoma Referral Center, SM Annunziata Hospital, Tuscan Tumor Institute, Florence, Italy*



**Vincent Brichard** 

*Vice President & Head of Immunotherapeutics at GlaxoSmithKline Biologicals, Belgium*

**Luana Calabrò** 

*Medical Oncology and Immunotherapy, University Hospital, Siena, Italy*

**Alessandra Cesano** 

*Clinical Affairs, Nodality Inc., South San Francisco, California*



**Michele Del Vecchio** 

*Unit of Medical Oncology 1, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy*

**Lex Eggermont** 

*Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, France*

# SPEAKERS and MODERATORS

**Mark Faries** 

*Department of Surgical Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California*

**Soldano Ferrone** 

*Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts*

**Thomas F. Gajewski** 

*Department of Pathology and Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois*

**Sacha Gnjatic** 


*Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York City, New York*

**Helen Gogas** 

*1st Department of Medicine, "Laiko" General Hospital, University of Athens, Greece*

**Mohamed Kashani-Sabet** 

*Center for Melanoma Research and Treatment, California Pacific Medical Center and CPMC Research Institute, San Francisco, California*



# SPEAKERS and MODERATORS



**Howard Kaufman** 🇺🇸

*The Tumor Immunology Laboratory & Department of General Surgery, Rush University Medical Center, Chicago, Illinois*

**James Larkin** 🇬🇧

*Department of Medicine, The Royal Marsden Hospital, London, UK*

**Paul V. Lehmann** 🇺🇸

*CEO of Cellular Technology Ltd and Adjunct Professor at CWRU, Cleveland, Ohio*



**Roger Lo** 🇺🇸

*Assistant Professor of Medicine/Dermatology & Molecular and Medical Pharmacology  
Director, Melanoma Clinic in Dermatology. Member, Jonsson Comprehensive Cancer Center,  
David Geffen School of Medicine at UCLA*

**Alberto Mantovani** 🇮🇹

*Istituto Clinico Humanitas IRCCS and Dept. Translational Medicine, University of Milan, Italy*

**Kim Margolin** 🇺🇸

*Medical Oncology, University of Washington, Seattle, Washington*



**Grant McArthur** 🇦🇺

*Divisions of Cancer Medicine and Cancer Research, Peter MacCallum Cancer Centre,  
Victoria, Australia*

# SPEAKERS and MODERATORS

**Cornelis Melief** 

*Leiden University Medical center, Leiden, The Netherlands*

**Igor Puzanov** 

*Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee*

**Nicola Normanno** 

*Cell Biology and Biotherapy Unit, INT Fondazione G. Pascale, Naples, Italy*

**Giuseppe Palmieri** 

*Segretario IMI, Intergruppo Melanoma Italiano, Presidente Humana Onlus, Italy*

**Rienk Offringa** 

*Head Div. Molecular Oncology of Gastrointestinal Cancers, German Cancer Research Center, Heidelberg, Germany*

**Licia Rivoltini** 

*Unit of Immunotherapy of Human Tumours, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy*

**Barbara Seliger** 

*Institute of Medical Immunology, Martin-Luther-University Halle-Wittenberg, Saale, Germany*



# SPEAKERS and MODERATORS



**Jeff Sosman** 

*Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee*

**Magdalena Thurin** 

*Cancer Diagnosis Program, NCI, NIH, Rockville, Maryland*



# GENERAL INFORMATION

## **CME PROVIDER AND ORGANISING AGENCY:**




3P Solution Srl  
Via Carducci 12, 20123 Milan  
Phone +39 02 36631574 - +39 349 6485434  
Fax +39 02 89098927  
[www.3psolution.it](http://www.3psolution.it)  
[info@3psolution.it](mailto:info@3psolution.it)

## **CONGRESS VENUE:**

Royal Continental Hotel  
Via Partenope, 38-44  
80121 - Naples  
Phone +39 081 245 2068  
[www.royalgroup.it/royalcontinental/](http://www.royalgroup.it/royalcontinental/)

## **OFFICIAL LANGUAGE:**

The official language is English



# GENERAL INFORMATION



## **REGISTRATION:**

Only registered attendees will be admitted to the meeting.

The registration fee includes:

- participation in the scientific program
- CME credits
- coffee breaks and lunches for December, 3<sup>rd</sup>, 4<sup>th</sup>.
- congress bag



Participants are kindly requested to inform us about any dietary habit (i.e. food allergies/intolerances, vegetarian or vegan habits).

## **OFFICIAL CONGRESS DINNER:**

Official Congress dinner will be held on December 2<sup>nd</sup>.

It will be possible to register for the Congress dinner (€ 125,00) by contacting us at [info@melanomabridge.org](mailto:info@melanomabridge.org) or at the registration desk before December 2<sup>nd</sup> at 2 p.m.






# GENERAL INFORMATION



# BRIDGE MEETING ATTENDANCE





**E.C.M.**

Commissione Nazionale Formazione Continua

agenas. 



## **CONTINUING MEDICAL EDUCATION**

3P Solution has been accredited by the Ministry of Health as a CME Provider (code 327) and has a quality-management system that meets the requirements of UNI EN ISO 9001:2008, with CSQA certificate no. 23887.

Melanoma Bridge is accredited by the Italian Ministry of Health for 16 CME credits. The specialties and disciplines eligible for CME credits are: Medical Doctors, Pharmacists, Biologists, and Nurses.

This event has been accredited for 100 participants.

In order to receive credits, participants must:

1. Attend all the accredited sessions;
2. Complete the assessment test at the end of the congress (a grade of 75% must be obtained to receive CME credit);
3. Complete the evaluation questions at the end of the congress.

CME certificate attendance will be sent to the participants at the end of the evaluation procedure.

The educational material related to the event will be available to participants on the website [www.3psolution.it](http://www.3psolution.it) upon registration.

# ORGANIZED BY



**Fondazione Melanoma Onlus**



**Istituto Nazionale Tumori - IRCCS  
"Fondazione G.Pascale"**



**National Institutes of Health**



**Society for Immunotherapy of Cancer**



# UNDER THE AUSPICES



**Associazione Italiana di Oncologia Medica**



**European Society for Medical Oncology**



**Regione Campania**



**Comune di Napoli**



This CME event has been sponsored by an *unrestricted grant* from:

**GOLD SPONSOR**



**SILVER SPONSOR**



**SPONSOR**

